You have 9 free searches left this month | for more free features.

stage I adult diffuse mixed cell lymphoma

Showing 76 - 100 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)

Recruiting
  • B-Cell Lymphoma
  • +4 more
  • 19(T2)28z1xx TRAC T cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Feb 24, 2023

B-cell NHL, CLL Trial (CARCIK-CD19)

Not yet recruiting
  • B-cell NHL
  • CLL
  • CARCIK-CD19
  • (no location specified)
May 19, 2023

Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)

Recruiting
  • Grade 3a Follicular Lymphoma
  • +14 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Atlanta, Georgia
  • +1 more
May 31, 2022

DLBCL, Chronic Lymphocytic Leukemia, B Cell Malignancies Trial in Australia, United States (ABBV-525)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +3 more
  • Louisville, Kentucky
  • +6 more
Nov 14, 2022

Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage I Adult

Completed
  • Contiguous Stage II Adult Lymphoblastic Lymphoma
  • +5 more
  • Sacramento, California
    University of California Davis
Mar 8, 2022

Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma Trial in United

Recruiting
  • Acute Adult T-Cell Leukemia/Lymphoma
  • +3 more
  • Atlanta, Georgia
  • +13 more
Jan 26, 2023

Non Hodgkin Lymphoma Trial in Aurora (UCD19 CAR T Cells)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • UCD19 CAR T Cells
  • Aurora, Colorado
    University of Colorado Hospital
Sep 1, 2022

Ann Arbor Stage III DLBCL, Ann Arbor Stage IIX (Bulky) DLBCL, Ann Arbor Stage IV DLBCL Trial in United States (drug, other,

Suspended
  • Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
  • +20 more
  • Tucson, Arizona
  • +110 more
Jan 31, 2023

AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, Ann Arbor Stage I DLBCL Trial in United States

Completed
  • AIDS-Related Plasmablastic Lymphoma
  • +15 more
  • Montgomery, Alabama
  • +34 more
Feb 23, 2022

Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma Trial in Worldwide (RO6870810, Venetoclax, Rituximab)

Completed
  • Diffuse Large B-cell Lymphoma
  • High-Grade B-cell Lymphoma
  • Duarte, California
  • +8 more
Jan 21, 2022

Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Trial in Seattle (procedure, drug, biological, radiation)

Recruiting
  • Acute Leukemia
  • +18 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 26, 2022

Recurrent DLBCL, Recurrent Mantle Cell Lymphoma, Refractory DLBCL Trial in Duarte (Autologous

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +4 more
  • Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Mar 28, 2022

Diffuse Large B-cell Lymphoma, HIV Trial in Lilongwe (R-CHOP)

Active, not recruiting
  • Diffuse Large B-cell Lymphoma
  • HIV
  • Lilongwe, Malawi
    UNC Project, Lighthouse Trust
Oct 18, 2021

Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma Trial in Worldwide (DPX-Survivac,

Recruiting
  • Relapsed Diffuse Large B-cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • Fountain Valley, California
  • +44 more
Jan 20, 2023

Lymphoma, Large B-Cell, Diffuse Trial in Austria (Venetoclax, Obinutuzumab)

Completed
  • Lymphoma, Large B-Cell, Diffuse
  • Graz, Austria
  • +5 more
Feb 15, 2022

Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease, DLBCL Trial in Kampala (Rituximab and Hyaluronidase Human,

Recruiting
  • Burkitt Lymphoma
  • +2 more
  • Rituximab and Hyaluronidase Human
  • +8 more
  • Kampala, Uganda
    UCI-Fred Hutch Cancer Centre
Mar 9, 2022

Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor Trial in Utrecht

Recruiting
  • Anaplastic Large Cell Lymphoma, ALK-Positive
  • +2 more
  • Paris, France
  • +1 more
Sep 27, 2022

Diffuse Large B Cell Lymphoma Trial in Poland (Ofatumumab, Etoposide, Ifosfamid)

Completed
  • Diffuse Large B Cell Lymphoma
  • Wrocław, Dolnośląskie, Poland
  • +7 more
Dec 23, 2021

Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor, Metastatic Lung Non-Small Cell Carcinoma Trial in Seattle

Terminated
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +12 more
  • Laboratory Biomarker Analysis
  • ROR1 CAR-specific Autologous T-Lymphocytes
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 11, 2022

DLBCL, High Grade B-Cell Lymphoma Trial in United States (Venetoclax, Rituximab, Etoposide)

Completed
  • Diffuse Large B-Cell Lymphoma
  • High Grade B-Cell Lymphoma
  • Boston, Massachusetts
  • +5 more
Aug 23, 2022

Solid Tumor, Adult, Head Neck Cancer, Non Small Cell Lung Cancer Trial in Worldwide (CX-2029)

Active, not recruiting
  • Solid Tumor, Adult
  • +4 more
  • Birmingham, Alabama
  • +24 more
Aug 5, 2022

Lymphocytic Leukemia, Chronic, DLBCL Trial in Australia, United States (GDC-0853)

Completed
  • Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma
  • Stanford, California
  • +9 more
Jun 16, 2022

Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Columbus, Salt

Active, not recruiting
  • Prolymphocytic Leukemia
  • +4 more
  • Columbus, Ohio
  • +1 more
Apr 29, 2022

Recurrent DLBCL, Refractory DLBCL Trial in Sacramento (Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Chimeric Antigen Receptor T-Cell Therapy
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Mar 8, 2022